Acquisition of Apollo

RNS Number : 6568P
Assura PLC
19 February 2021
 

19 February 2021

Assura plc

Acquisition of Apollo to further strengthen development pipeline and capability

Assura plc ("Assura" or "the Company"), the UK's leading primary care property investor and developer, today announces that it has completed the acquisition of primary care developer Apollo Capital Projects Development Limited ("Apollo").

Apollo has a strong, 20-year track record of developing high-quality primary care properties across the UK, with a very experienced four-person development team. As well as expanding the Assura development team to 11 specialist surveyors, the acquisition increases our immediate and extended development pipeline by an initial eight schemes with an estimated total capital expenditure of £50 million.

In addition, the current live development scheme at Beaconsfield will be converted from a forward-fund to an in-house development.

Jonathan Murphy, CEO, said: "The acquisition of Apollo will further enhance our sector-leading in-house development capabilities and substantially expand our pipeline, which is already the largest in our history.

"Following our acquisition of primary care developer GPI in 2019, this is another important step in our growth story that further deepens our understanding of the future trends shaping the sector, from building design to sustainability.

"Expanding our offer to the NHS as its partner of choice has never been more vital than it is today. As Apollo's colleagues integrate into Assura, we look forward to working together to continue creating outstanding spaces for health services in our communities."

- ENDS -

For more information, please contact:

Assura plc

Jayne Cottam, CFO
David Purcell, Head of Investor Relations

Tel: 01925 420660

Email: Investor@assura.co.uk

Finsbury

Gordon Simpson
James Thompson

Tel: 0207 251 3801

Email: Assura@finsbury.com

 This announcement contains inside information as defined in Article 7 of the EU Market Abuse Regulation No 596/2014 and has been announced in accordance with the Company's obligations under Article 17 of that Regulation.

 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2020, Assura's property portfolio was valued at £2,259 million.

 

Further information is available at www.assuraplc.com

 

*EPRA is a registered trademark of the European Public Real Estate Association.

 

Assura plc LEI code: 21380026T19N2Y52XF72

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUWVARAOUUAUR

Companies

Assura (AGR)
UK 100

Latest directors dealings